Trial of AD036 in Obstructive Sleep Apnea

Obstructive Sleep Apnea Clinical Trial

Official title:

Phase 2, Placebo-Controlled, Parallel Group Dose-Finding Study to Evaluate the Efficacy and Safety of Three Dose Levels of AD036 in Adults With Obstructive Sleep Apnea

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03845023
• Other study ID #: APN-002
• Status: Completed
• Phase: Phase 2
• Start date: March 7, 2019
• Est. completion date: October 23, 2019

Study information

• Verified date: November 2022
• Source: Apnimed
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, double blind, placebo-controlled, repeat-dose, parallel arm, outpatient and inpatient phase 2 clinical study to examine the efficacy and safety of three dose levels of AD036 versus placebo in patients with obstructive sleep apnea.

Description:

This was a randomized, double-blind, placebo-controlled, repeat-dose, parallel arm, outpatient and inpatient, multicenter, dose-finding study of the combination of atomoxetine and oxybutynin in adults with OSA documented by polysomnography (PSG).

Approximately 140 subjects were to be randomized 1:1:1:1 to receive 1 of 3 different fixed-dose combinations of oxybutynin and atomoxetine or matching placebo.

For all subjects, the study consisted of:

• A screening and baseline period in which subjects' eligibility was determined

• An initial 2-night, at-home blinded baseline period in which all subjects received placebo

• A 3-night, run-in period in which subjects received:

• Low-dose combination for subjects randomized to one of the 3 study treatment arms

• Placebo for subjects randomized to the placebo treatment arm

• A 7-night treatment period in which subjects received the treatment to which they were randomized, i.e., 1 of the 3 different fixed-dose combinations of drugs, or placebo

• An end of study visit

Recruitment information / eligibility

• Status: Completed
• Enrollment: 140
• Est. completion date: October 23, 2019
• Est. primary completion date: October 23, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 25 Years to 70 Years

Eligibility

Male participants between 25 to 65 years of age or female participants between 25 to 70 years of age.

Key Inclusion Criteria:

• AHI = 20 based on screening polysomnography

• Epworth Sleepiness Scale (ESS) score = 4 for participants not using CPAP

• Previous surgical treatment for OSA is allowed if = 1 year prior to enrollment

Key Exclusion Criteria:

• Clinically significant craniofacial malformation.

• Clinically significant cardiac disease (e.g., rhythm disturbances, coronary artery disease or cardiac failure) or hypertension requiring more than 2 medications for control.

• Clinically significant neurological disorder, including epilepsy/convulsions.

• Positive screen for drugs of abuse or substance use disorder as defined in DSM-V within 24 months prior to Screening Visit.

• A significant illness or infection requiring medical treatment in the past 30 days.

• Women who are pregnant or nursing.

• History of using oral or nasal devices for the treatment of OSA may enroll as long as the devices are not used during participation in the study.

• History of using devices to affect participant sleeping position for the treatment of OSA, e.g. to discourage supine sleeping position, may enroll as long as the devices are not used during participation in the study.

• Treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors, strong cytochrome P450 2D6 (CYP2D6) inhibitors, or monoamine oxidase inhibitors (MAOI) within 14 days of the start of treatment, or concomitant with treatment.

• Use of another investigational agent within 90 days or 5 half-lives, whichever is longer, prior to dosing.

• ESS total score > 18.

• Central apnea index > 5/hour on baseline PSG.

• Periodic limb movement arousal index >15/hour on baseline PSG.

• Hepatic transaminases >3X the upper limit of normal (ULN), total bilirubin >2X ULN (unless confirmed Gilbert syndrome), serum creatinine >2X ULN.

• <6 hours typical sleep duration.

• Night- or shift-work sleep schedule.

• Employment as a commercial driver or operator of heavy or hazardous equipment.

Related Conditions & MeSH terms

• Apnea
• Obstructive Sleep Apnea
• Sleep Apnea Syndromes
• Sleep Apnea, Obstructive

Intervention

Drug:
• AD036 Dose 1
AD036 Dose 1 oral capsule administered before sleep
• AD036 Dose 2
AD036 Dose 2 oral capsule administered before sleep
• AD036 Dose 3
AD036 Dose 3 oral capsule administered before sleep
• Placebo
Placebo oral capsule administered before sleep

Locations

Country	Name	City	State
United States	Sleep Medicine & Research Center, St. Luke's Hospital	Chesterfield	Missouri
United States	The Center for Sleep and Wake Disorders	Chevy Chase	Maryland
United States	Northwestern University	Chicago	Illinois
United States	CTI Clinical Research Center	Cincinnati	Ohio
United States	Pulmonary Associates	Glendale	Arizona
United States	Preferred Research Partners, Inc.	Little Rock	Arkansas
United States	Norton Clinical Research Group	Louisville	Kentucky
United States	Clinilabs Drug Development Corporation	New York	New York
United States	Stanford Sleep Medicine	Redwood City	California
United States	Sleep Therapy & Research Center	San Antonio	Texas
United States	SDS Clinical Trials, Inc.	Santa Ana	California
United States	Santa Monica Clinical Trials	Santa Monica	California

Sponsors (1)

Lead Sponsor	Collaborator
Apnimed

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Apnea Hypopnea Index (AHI)	Number of participants with =50% reduction in apnea hypopnea index (AHI). AHI is the average number of apneas and hypopneas a person experiences each hour during sleep, to register as an event an apnea or hypopnea must last at least 10 seconds or longer. To measure this, doctors divide the total number of apneic and hypopneic events by the total number of hours the person was asleep.	10 days